Emerging ResearchPeptide

KPV

Lys-Pro-Val

Anti-Inflammatory Tripeptide

Last updated: August 2026

Evidence Level: Emerging Research

Very new, early-stage research, high uncertainty

Regulatory Status: Not FDA-approved. Placed in FDA 503A Category 2 in 2023. On July 23, 2026 an FDA advisory committee voted 8 to 6 to recommend adding it to the permitted 503A list. That vote is advisory and non-binding; nothing has legally changed yet.

KPV is the smallest active piece of alpha-MSH, a hormone your body uses to switch off inflammation. It is just three amino acids: lysine, proline, valine. In mouse models of colitis it reduces inflammation substantially, including when given orally. No controlled human trial of KPV has ever been published.

How It Works

Alpha-melanocyte-stimulating hormone is a 13-amino-acid hormone with a genuinely broad anti-inflammatory effect. Researchers worked out that most of that anti-inflammatory activity lives in the last three amino acids of the chain: lysine, proline, valine. KPV is that fragment, isolated.

Why the small size matters. Three amino acids is tiny for a peptide. That makes it cheap to synthesize, stable enough to survive some digestion, and small enough to get taken up directly by intestinal cells. Most peptides have to be injected. KPV has real oral activity in animal models, which is unusual and is the main reason it is interesting for gut conditions specifically.

What it does inside the cell. KPV appears to get into cells and interfere with NF-kB, a master switch that turns on inflammatory gene expression. Block NF-kB signaling and you turn down the production of inflammatory cytokines like TNF-alpha and IL-6 at the source, rather than mopping them up after the fact. It also appears to act on melanocortin receptors, though the intracellular route may matter more.

The animal evidence is genuinely good. KPV has been tested in the two standard rodent models of inflammatory bowel disease, DSS-induced colitis and TNBS-induced colitis. Oral KPV reduced inflammatory cytokine expression and lowered disease severity across multiple models. In the context of preclinical work, that is a solid, replicated result.

And then it stops. No controlled human clinical trial of KPV has been published for any condition. Not for inflammatory bowel disease, not for skin inflammation, not for anything. Everything you will read about KPV in humans is either extrapolation from mice or a clinic reporting on its own patients without a control group.

That gap is the entire story of KPV. The biology is credible, the animal work is real and replicated, and the human evidence is absent. Those three facts should be held together.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Gut healthPreclinical
SkinPreclinical

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Gut healthPreclinical certainty

Reduces intestinal inflammation.

Population: No human population has been studied. Evidence is from mouse colitis models and cultured intestinal cells.

Why this rating

The animal evidence is unusually consistent for a research peptide: KPV reduced inflammation across multiple independent rodent colitis models, including with oral dosing, and the intracellular mechanism is well characterized. But no controlled human trial of KPV has been published for any condition. Rodent colitis models have a poor record of predicting human IBD results, which is why several drugs that cured mice failed in people.

Supporting studies

KPV in DSS and TNBS-induced colitis modelsAnimal Study
2013
Reduced pro-inflammatory cytokine expression and disease severity across multiple rodent colitis models.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

SkinPreclinical certainty

Reduces skin inflammation when applied topically.

Population: No human population has been studied in a controlled trial.

Why this rating

Alpha-MSH and its fragments have documented anti-inflammatory activity in skin models, and KPV is marketed heavily for topical use. We could not identify a controlled human trial of topical KPV for any skin condition. This claim rests on mechanism plus animal data from the parent hormone.

Supporting studies

Anti-inflammatory activity of alpha-MSH C-terminal tripeptideIn-Vitro
2008
KPV reduced inflammatory signaling in cell models, including skin-relevant cell types.

Reviewed 2026-08-24· Designing Longevity EditorialHow we grade

Potential Benefits

Consistently reduced inflammation across multiple independent rodent colitis models
Orally active in animal studies, unusual for a peptide and useful for targeting the gut directly
Targets NF-kB, an upstream inflammatory switch, rather than a single downstream cytokine
Very small and structurally simple, which makes it cheap to make and relatively stable
No serious safety signals reported in the animal work conducted so far
An FDA advisory committee voted in July 2026 to recommend it for the permitted compounding list

Risks & Considerations

No published controlled human trial for any condition. Every human claim is an extrapolation
No human dosing, absorption, or safety data exists in the published literature
Suppressing NF-kB is suppressing a core immune pathway, and the long-term consequences of doing so in humans are unstudied
Marketed aggressively for inflammatory bowel disease, a serious condition where delaying proven treatment causes real harm
Unregulated supply with no verified identity, purity, or dose
The July 2026 advisory vote is not approval, and FDA rulemaking typically takes 12 to 24 months

Dosing Information

There is no established human dose because there has never been a human dose-finding study. The figures circulating online are clinic convention, not trial data.

•Commonly suggested oral doses are 250 to 500mcg daily, with no published human basis
•Oral capsules are favored for gut-targeted use, which is at least consistent with the animal data
•Topical preparations are used for skin inflammation, an application with even less evidence
•Animal study doses do not translate directly to humans by body weight
•We are not publishing a protocol for a compound with zero human safety data

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

1If you have diagnosed inflammatory bowel disease, treat KPV as an experiment on top of real treatment, never as a replacement for it
2Untreated IBD causes cumulative bowel damage. This is not a condition where waiting to see if a research peptide works is a low-cost choice
3Tell your gastroenterologist. Anti-inflammatory effects can mask disease activity and confuse monitoring
4If you try it, use objective markers (fecal calprotectin, CRP) rather than symptoms alone to judge whether anything is happening
5Watch the FDA rulemaking after the July 2026 advisory vote. If KPV makes the 503A list, quality control improves substantially
6Be skeptical of clinics quoting response rates. Without a control group, those numbers are not measuring the drug

Key Research

Nanoparticles containing KPV attenuate DSS-induced colitis in mice

Biomaterials / Journal of Controlled Release, 2013

Orally delivered KPV reduced inflammatory cytokine expression and attenuated colitis severity in mice at doses far lower than free peptide.

KPV inhibits inflammatory signaling in intestinal epithelial and immune cells

American Journal of Physiology / Gastroenterology, 2008

KPV is taken up by intestinal epithelial cells via the PepT1 transporter and reduces NF-kB activation and pro-inflammatory cytokine production.

FDA Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026

FDA advisory committee proceedings, 2026

The committee voted 8 to 6, with one abstention, to recommend KPV for the 503A bulk drug substances list. The vote is advisory and does not change KPV's legal status without subsequent FDA rulemaking.

View Study

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All Treatments Find Your Goal

Always consult a healthcare provider before starting any treatment.This treatment has very early human evidence.

Frequently Asked Questions

What is KPV?

KPV is a three-amino-acid peptide (lysine, proline, valine) that makes up the tail end of alpha-MSH, a hormone your body uses to shut down inflammation. Researchers found that most of alpha-MSH's anti-inflammatory activity lives in that fragment, so KPV isolates it. It is one of the smallest bioactive peptides in common use.

Does KPV work for inflammatory bowel disease?

In mice, convincingly. Oral KPV reduced inflammation and disease severity across multiple standard rodent colitis models, and the results have been reproduced by different groups. In humans, nobody knows, because no controlled human trial has been published. IBD is an area where several drugs that worked beautifully in mice did nothing in people, so the gap matters.

Is KPV legal?

Its status is in flux. The FDA placed KPV in Category 2 of the interim 503A bulk substances list in 2023, flagging safety concerns. On July 23, 2026 an FDA advisory committee voted 8 to 6 to recommend adding KPV to the permitted 503A list. That vote is advisory and non-binding. Actually changing KPV's legal status requires formal FDA rulemaking, which typically takes 12 to 24 months, so nothing has changed yet.

Can you take KPV orally?

The animal evidence suggests yes, which is unusual for a peptide. KPV is small enough to be picked up directly by intestinal cells through a transporter called PepT1, so it does not have to survive the whole digestive process intact the way a larger peptide would. That is the main reason oral capsules are the common form. Whether the same absorption happens in humans has not been published.

What is the difference between KPV and BPC-157 for gut health?

They target different things. BPC-157 is studied mainly for repairing physical damage to the gut lining, such as ulcers and NSAID injury. KPV targets the inflammatory signaling itself by interfering with NF-kB. Neither has controlled human trials. If your problem is inflammation, KPV is the mechanistically better fit; if it is tissue damage, BPC-157 is.

Are there side effects from KPV?

No serious safety signals appeared in the animal studies conducted, and no human safety data exists to report. That absence is not reassurance. KPV works by suppressing NF-kB, which is a core immune signaling pathway, and what long-term suppression of that pathway does in a human body has not been studied.

Should I use KPV instead of my IBD medication?

No. Untreated or undertreated inflammatory bowel disease causes cumulative, permanent bowel damage, and the approved treatments have decades of outcome data. KPV has zero controlled human trials. If you want to try it, do it in addition to real treatment, tell your gastroenterologist, and track objective markers like fecal calprotectin rather than how you feel.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Compare KPV

KPV vs BPC-157

Two gut peptides that work on different problems

Related Peptides

BPC-157Cytoprotective Peptide

Thymosin Alpha-1Immune-Modulating Peptide

KPV